Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Accured Expenses (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Change in Accured Expenses for 7 consecutive years, with -$118000.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 104.1% to -$118000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.5 million through Dec 2025, down 99.68% year-over-year, with the annual reading at -$2.5 million for FY2025, 99.68% down from the prior year.
  • Change in Accured Expenses hit -$118000.0 in Q4 2025 for Allogene Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $8.9 million in Q3 2021 to a low of -$12.7 million in Q3 2023.
  • Historically, Change in Accured Expenses has averaged -$260200.0 across 5 years, with a median of $686000.0 in 2023.
  • Biggest YoY gain for Change in Accured Expenses was 906.99% in 2024; the steepest drop was 1140.51% in 2024.
  • Year by year, Change in Accured Expenses stood at -$2.8 million in 2021, then skyrocketed by 213.33% to $3.1 million in 2022, then crashed by 90.88% to $286000.0 in 2023, then skyrocketed by 906.99% to $2.9 million in 2024, then crashed by 104.1% to -$118000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for ALLO at -$118000.0 in Q4 2025, $1.1 million in Q3 2025, and $1.7 million in Q2 2025.